Niagen Bioscience Inc (NAGE)
Valuation Overview•Is Niagen Bioscience Inc Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
High-quality fundamentals with a strong composite quality score of 77/100, backed by robust profitability and solvency.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street is highly bullish, projecting significant upside with steady expected earnings growth. However, capital return yields remain modest, driven predominantly by aggressive share repurchases.
NAGE demonstrates strong business quality with robust profitability and healthy margins (highlighted by a massive 114.1% ROIC). This is backed by a fortress balance sheet, holding significant net cash ($62M) and minimal debt risk.
The company is driving exceptional top-line expansion (21.6% 3Y CAGR) paired with stable bottom-line earnings. Operating efficiency remains adequate with margins around 8.5%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $31.5M | +29.9% | +21.6% | +16.9% | +21.9% | |
| EBITDA | $1.9M | — | — | — | — | |
| Net Income | $6.3M | +103.3% | — | — | — | |
| EPS (Diluted) | $0.07 | +81.8% | — | — | — | |
| Free Cash Flow | -$1.3M | +10.0% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 64.3% | 62.3% | 61.6% | 57.1% |
| Operating Margin | 8.5% | 4.0% | -10.8% | -35.1% |
| Net Margin | 14.3% | 5.4% | -9.4% | -32.3% |
| FCF Margin | 3.1% | 10.2% | -5.5% | -23.6% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.06 | $0.07 | +16.7% | ||
| Q1'26 | $0.02 | $0.03 | +50.0% | ||
| Q4'25 | $0.01 | $0.05 | +233.3% | ||
| Q3'25 | $0.02 | $0.04 | +100.0% | ||
| Q2'25 | $0.02 | $0.04 | +100.0% | ||
| Q1'25 | $0.02 | $0.03 | +50.0% | ||
| Q4'24 | $0.01 | $0.02 | +100.0% | ||
| Q2'24 | $-0.02 | $-0.00 | +99.0% |
Total return is -75.6% (1Y), lagging the benchmark by -96.4%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -44.8% | -52.1% | — |
| 1Y | -75.6% | -96.4% | — |
| 3YCAGR | +29.7% | +7.9% | — |
| 5YCAGR | -17.7% | -29.2% | — |
| 10YCAGR | +1.8% | -13.0% | — |
The S&P 500 is at 30.6x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Niagen Bioscience Inc (NAGE) valuation, health, and returns.
Based on peer relative multiples, Niagen Bioscience Inc appears Cheap versus peers compared to industry peers.
Niagen Bioscience Inc has multiple valuation anchors: Peer Relative Fair Value: $4.84 | Wall Street Analyst Target: $10.50 (implying +207.0% upside). A convergence of these signals offers higher conviction.
Niagen Bioscience Inc displays good financial health with a composite quality score of 77/100, supported by a Altman Z-Score of 5.7 (safe zone), Piotroski F-Score of 6/9, Return on Invested Capital (ROIC) of 114.1%.
Niagen Bioscience Inc does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Niagen Bioscience Inc's current growth trajectory is Accelerating. The company achieved +29.9% 1Y revenue growth and +81.8% 1Y EPS growth, compared to its 3Y revenue CAGR of +21.6%.
Wall Street consensus is Buy based on 5 analysts, beating EPS expectations in 100% of recent quarters with a 18-quarter streak. The consensus price target represents a +207.0% change from current levels.
Investment risks for Niagen Bioscience Inc include: -77.0% 1-year max drawdown, high beta (1.36x market volatility). Volatility risk is characterized by a beta of 1.36x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.